EDIT shows strong overbought momentum with clean engine gates and a solid recent earnings-beat record, but severe cash burn and a sharply declining revenue base keep quality metrics below the platform floor.
Thesis pillars
- Overbought Momentum Clean Gates→Stable
- Severe Cash Burn→Stable
- Declining Revenue Base→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 9, 2026· older than 90 days
Editas Medicine, Inc. (EDIT) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $2.72: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 1.33; Below-average business quality.
Editas Medicine is a clinical-stage gene editing company developing CRISPR-based genomic medicines, with lead candidate EDIT-401 — an in vivo therapy designed to reduce LDL-cholesterol by upregulating the LDL receptor gene — in preclinical development ahead of a planned IND... Read more
Sell if holding. Engine safety override at $2.72: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 1.33; Below-average business quality. Chart setup: RSI 59 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 5/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on SEC filing concern and earnings proximity 4d<=7d. Suitability: speculative.
About Editas Medicine, Inc.
About Editas Medicine, Inc.
Editas Medicine is advancing EDIT-401, an in vivo CRISPR therapy designed to reduce LDL-cholesterol by upregulating the LDL receptor gene, toward an IND submission targeted for mid-2026 after the candidate achieved LDL-C reductions of 90% or more in non-human primate studies. The company reported a $160.1 million net loss in 2025 and held cash sufficient to fund operations into the third quarter of 2027.
Editas built its platform around CRISPR/Cas9 and CRISPR/Cas12a gene editing enzymes, which it licenses exclusively from the Broad Institute and Harvard for human medicines, and applies a functional-upregulation strategy that edits non-coding regulatory DNA rather than protein-coding sequences. Beyond EDIT-401, the company is developing an in vivo hematopoietic stem cell editing approach for sickle cell disease and transfusion-dependent beta thalassemia, building on its earlier ex vivo program, reni-cel, which it discontinued commercializing in December 2024. Editas also generates non-dilutive funding through partnerships: its collaboration with Bristol Myers Squibb's Juno Therapeutics subsidiary has produced 14 programs using Editas's Cas9 and AsCas12a platforms, and its 2023 license agreement with Vertex Pharmaceuticals for ex vivo Cas9 technology underlying CASGEVY generated a $50.0 million upfront payment plus ongoing annual license fees.
Show full overview
Editas frames EDIT-401 as carrying outsized weight for the entire company: the 10-K states that because the business is significantly dependent upon this one product candidate, any clinical, regulatory, or manufacturing setback would materially harm the company's prospects. That concentration is compounded by novelty risk — only one CRISPR-based gene editing therapeutic has ever been approved in the United States or Europe, and it was an ex vivo product, while no in vivo CRISPR therapeutic like EDIT-401 has yet received approval anywhere.
See also: Healthcare · Biotechnology
From Editas Medicine, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated Nov 2, 2026Recent Developments — Editas Medicine, Inc.
Latest news
- NEWS Editas Medicine, Inc. Scheduled to Announce Q3 2026 Financial Results — fiscal.ai Nov 2, 2026 neutral
- NEWS Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6 — benzinga Oct 8, 2026
- NEWS Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozyg — benzinga Oct 8, 2026
- NEWS TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday — benzinga Sep 23, 2026
- NEWS This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday — benzinga Sep 23, 2026 positive
Latest item Nov 2, 2026 · Generated 2026-11-05T11:54:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineEDIT-40110-K Item 1A: 'We are dependent on the success of our lead product candidate, EDIT-401 ... our business is significantly dependent upon this one product candidate'
Material Events(8-K, last 90d)
- 2026-04-07Item 4.01HIGHEditas Medicine dismissed Ernst & Young as its independent registered public accounting firm effective April 1, 2026, following a competitive review, and appointed PricewaterhouseCoopers LLP as its new auditor for fiscal year 2026. Ernst & Young's prior reports on FY2024 and FY2025 financials contained no adverse opinion, disclaimer, or qualification.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Volatile — 7.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $2.72: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 1.33; Below-average business quality. Chart setup: RSI 59 mid-range, Bollinger mid-band. Prior stop was $2.53. Score 5.3/10, moderate confidence.
Analyst target: $5.31 (+95.1% upside). Prior stop was $2.53. Stop-loss: $2.53.
Concentration risk — Pipeline: EDIT-401; Quality below floor (3.3 < 4.0).
Editas Medicine, Inc. trades at a P/E of N/A (forward -3.6). TrendMatrix value score: 7.1/10. Verdict: Sell.
19 analysts rate EDIT, with a consensus score of 3.9/5. 10 analysts publish price targets averaging $6.
What does Editas Medicine, Inc. do?Editas Medicine is a clinical-stage gene editing company developing CRISPR-based genomic medicines, with lead candidate...
Editas Medicine is a clinical-stage gene editing company developing CRISPR-based genomic medicines, with lead candidate EDIT-401 — an in vivo therapy designed to reduce LDL-cholesterol by upregulating the LDL receptor gene — in preclinical development ahead of a planned IND submission by mid-2026. The company has never generated product revenue, reported a $160.1 million net loss in 2025 against a $1.6 billion accumulated deficit, and funds operations through equity offerings, its BMS collaboration, and licensing payments from Vertex Pharmaceuticals.